Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis

Biochemical and Biophysical Research Communications

Volumn 458, Issue 1, 2015, Pages 52-56

  Kogita, Akihiro ^a   Yoshioka, Yasumasa ^a   Sakai, Kazuko ^a   Togashi, Yosuke ^a   Sogabe, Shunsuke ^a   Nakai, Takuya ^a   Okuno, Kiyotaka ^a   Nishio, Kazuto ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Heterogeneity; RAS mutation

Indexed keywords

APC PROTEIN; BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 3; OXALIPLATIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN P53; SMAD4 PROTEIN; ERBB4 PROTEIN, HUMAN; FGFR3 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN; SMAD4 PROTEIN, HUMAN;

ADULT; AGED; AMINO ACID SEQUENCE; APC GENE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; COLON CARCINOMA; COLON RESECTION; EPIDERMAL GROWTH FACTOR RECEPTOR 4 GENE; FBXW7 GENE; FEMALE; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; GENE FREQUENCY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARS GENE; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; PARTIAL HEPATECTOMY; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE GENE; POINT MUTATION; PRIMARY TUMOR; PRIORITY JOURNAL; SMAD4 GENE; SOMATIC MUTATION; SUBSEGMENTAL HEPATECTOMY; TP53 GENE; VERY ELDERLY; COLONIC NEOPLASMS; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES;

AGED, 80 AND OVER; COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, ERBB-4; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SMAD4 PROTEIN;

EID: 84922867583     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.01.064     Document Type: Article

References (29)

1. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, H. Comber, D. Forman, and F. Bray Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur. J. Cancer 49 2013 1374 1403
2. C.E. DeSantis, C.C. Lin, A.B. Mariotto, R.L. Siegel, K.D. Stein, J.L. Kramer, R. Alteri, A.S. Robbins, and A. Jemal Cancer treatment and survivorship statistics, 2014 CA A Cancer J. Clin. 64 2014 252 271
3. A.M. Marques, A. Turner, and R.A. de Mello Personalizing medicine for metastatic colorectal cancer: current developments World J. Gastroenterol. WJG 20 2014 10425 10431
4. H. Brenner, M. Kloor, and C.P. Pox Colorectal cancer Lancet 383 2014 1490 1502
5. R. Siegel, C. Desantis, and A. Jemal Colorectal cancer statistics, 2014 CA A Cancer J. Clin. 64 2014 104 117
6. K.H. Lee, J.S. Kim, K.S. Cheon, I.S. Song, D.Y. Kang, and J.Y. Kim TisN0M1 sigmoid colon cancer: a case report Ann. Coloproctol. 30 2014 141 146
7. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, S. Begum, N.Q. McDonald, A. Butler, D. Jones, K. Raine, C. Latimer, C.R. Santos, M. Nohadani, A.C. Eklund, B. Spencer-Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P.A. Futreal, and C. Swanton Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 366 2012 883 892
8. S.P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha, Y. Zhao, G. Turashvili, J. Ding, K. Tse, G. Haffari, A. Bashashati, L.M. Prentice, J. Khattra, A. Burleigh, D. Yap, V. Bernard, A. McPherson, K. Shumansky, A. Crisan, R. Giuliany, A. Heravi-Moussavi, J. Rosner, D. Lai, I. Birol, R. Varhol, A. Tam, N. Dhalla, T. Zeng, K. Ma, S.K. Chan, M. Griffith, A. Moradian, S.W. Cheng, G.B. Morin, P. Watson, K. Gelmon, S. Chia, S.F. Chin, C. Curtis, O.M. Rueda, P.D. Pharoah, S. Damaraju, J. Mackey, K. Hoon, T. Harkins, V. Tadigotla, M. Sigaroudinia, P. Gascard, T. Tlsty, J.F. Costello, I.M. Meyer, C.J. Eaves, W.W. Wasserman, S. Jones, D. Huntsman, M. Hirst, C. Caldas, M.A. Marra, and S. Aparicio The clonal and mutational evolution spectrum of primary triple-negative breast cancers Nature 486 2012 395 399
9. D.P. Lane Cancer. p53, guardian of the genome Nature 358 1992 15 16
10. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
11. N.S. Fearnhead, M.P. Britton, and W.F. Bodmer The ABC of APC Hum. Mol. Genet. 10 2001 721 733
12. D.J. Jonker, C.J. O'Callaghan, C.S. Karapetis, J.R. Zalcberg, D. Tu, H.J. Au, S.R. Berry, M. Krahn, T. Price, R.J. Simes, N.C. Tebbutt, G. van Hazel, R. Wierzbicki, C. Langer, and M.J. Moore Cetuximab for the treatment of colorectal cancer N. Engl. J. Med. 357 2007 2040 2048
13. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O'Callaghan, D. Tu, N.C. Tebbutt, R.J. Simes, H. Chalchal, J.D. Shapiro, S. Robitaille, T.J. Price, L. Shepherd, H.J. Au, C. Langer, M.J. Moore, and J.R. Zalcberg K-ras mutations and benefit from cetuximab in advanced colorectal cancer N. Engl. J. Med. 359 2008 1757 1765
14. C. Bokemeyer, I. Bondarenko, J.T. Hartmann, F. de Braud, G. Schuch, A. Zubel, I. Celik, M. Schlichting, and P. Koralewski Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 22 2011 1535 1546
15. E. Van Cutsem, C.H. Kohne, I. Lang, G. Folprecht, M.P. Nowacki, S. Cascinu, I. Shchepotin, J. Maurel, D. Cunningham, S. Tejpar, M. Schlichting, A. Zubel, I. Celik, P. Rougier, and F. Ciardiello Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29 2011 2011 2019
16. M. Narahara, K. Higasa, S. Nakamura, Y. Tabara, T. Kawaguchi, M. Ishii, K. Matsubara, F. Matsuda, and R. Yamada Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants PloS One 9 2014 e100924
17. S. Iida, H. Hasegawa, K. Okabayashi, K. Moritani, M. Mukai, and Y. Kitagawa Risk factors for postoperative recurrence in patients with pathologically T1 colorectal cancer World J. Surg. 36 2012 424 430
18. P.H. Seeburg, W.W. Colby, D.J. Capon, D.V. Goeddel, and A.D. Levinson Biological properties of human c-Ha-ras1 genes mutated at codon 12 Nature 312 1984 71 75
19. C.C. Chen, T.K. Er, Y.Y. Liu, J.K. Hwang, M.J. Barrio, M. Rodrigo, E. Garcia-Toro, and M. Herreros-Villanueva Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations PloS One 8 2013 e55793
20. S. Kang, A.G. Bader, and P.K. Vogt Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic Proc. Natl. Acad. Sci. U. S. A. 102 2005 802 807
21. N.I. Fleming, R.N. Jorissen, D. Mouradov, M. Christie, A. Sakthianandeswaren, M. Palmieri, F. Day, S. Li, C. Tsui, L. Lipton, J. Desai, I.T. Jones, S. McLaughlin, R.L. Ward, N.J. Hawkins, A.R. Ruszkiewicz, J. Moore, H.J. Zhu, J.M. Mariadason, A.W. Burgess, D. Busam, Q. Zhao, R.L. Strausberg, P. Gibbs, and O.M. Sieber SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer Cancer Res. 73 2013 725 735
22. M.P. de Caestecker, P. Hemmati, S. Larisch-Bloch, R. Ajmera, A.B. Roberts, and R.J. Lechleider Characterization of functional domains within Smad4/DPC4 J. Biol. Chem. 272 1997 13690 13696
23. M. Koyama, M. Ito, H. Nagai, M. Emi, and Y. Moriyama Inactivation of both alleles of the DPC4/SMAD4 gene in advanced colorectal cancers: identification of seven novel somatic mutations in tumors from Japanese patients Mutat. Res. 406 1999 71 77
24. K. Kojima, S.M. Vickers, N.V. Adsay, N.C. Jhala, H.G. Kim, T.R. Schoeb, W.E. Grizzle, and C.A. Klug Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia Cancer Res. 67 2007 8121 8130
25. L. Leung, N. Radulovich, C.Q. Zhu, D. Wang, C. To, E. Ibrahimov, and M.S. Tsao Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis PloS One 8 2013 e84366
26. W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, K.T. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. De Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Di Fiore, A.O. Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, T.P. Hansen, E. Van Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi, and S. Tejpar Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol. 11 2010 753 762
27. J.Y. Douillard, K.S. Oliner, S. Siena, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem, F. Rivera, I. Kocakova, P. Ruff, M. Blasinska-Morawiec, M. Smakal, J.L. Canon, M. Rother, R. Williams, A. Rong, J. Wiezorek, R. Sidhu, and S.D. Patterson Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N. Engl. J. Med. 369 2013 1023 1034
28. S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, E. Valtorta, R. Schiavo, M. Buscarino, G. Siravegna, K. Bencardino, A. Cercek, C.T. Chen, S. Veronese, C. Zanon, A. Sartore-Bianchi, M. Gambacorta, M. Gallicchio, E. Vakiani, V. Boscaro, E. Medico, M. Weiser, S. Siena, F. Di Nicolantonio, D. Solit, and A. Bardelli Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
29. M. Murtaza, S.J. Dawson, D.W. Tsui, D. Gale, T. Forshew, A.M. Piskorz, C. Parkinson, S.F. Chin, Z. Kingsbury, A.S. Wong, F. Marass, S. Humphray, J. Hadfield, D. Bentley, T.M. Chin, J.D. Brenton, C. Caldas, and N. Rosenfeld Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA Nature 497 2013 108 112